Blood Markers in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy
Studies blood samples from people with spreading leiomyosarcoma who are receiving chemotherapy.
Key facts
- Who runs it
- University of Michigan Rogel Cancer Center
- Where
- Ann Arbor, Boston, Columbus, Houston, Miami, Nashville, New York, Rochester, and Santa Monica, United StatesSee the 9 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Metastatic Leiomyosarcoma Biomarker Protocol
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 22 Dec 2022
- Expected to end
- Dec 2026
- Type of study
- Observational
- Treatments tested
- Plasma Collection
- Record updated
- 24 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with leiomyosarcoma that cannot be removed by surgery or has spread. They must be starting first-line chemotherapy. Blood and tumor samples are studied as markers of how well treatment works.
- Age
- No age requirement.
- Sex
- All sexes can join.
- Disease stage
- Leiomyosarcoma that cannot be removed by surgery (unresectable) or has spread (metastatic), with target lesions per RECIST 1.1.
- Earlier treatment
- Receiving first-line chemotherapy with doxorubicin-based treatment or gemcitabine/docetaxel.
- Biomarker or test result
- No specific biomarker is required. Archival tumor tissue (slides or a tissue block, or a fresh frozen sample) is optional for the research.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement
- Receiving first-line chemotherapy with doxorubicin- based or gemcitabine/docetaxel
- Target lesions per RECIST 1.1
- Optional archival tumor tissue including 1 H\&E-stained slide and unstained tumor tissue [either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample] available for study research
Where in United States
Also in 1 other country, 2 sites
- University of Michigan Cancer CenterAnn Arbor, United StatesContact: Scott Schuetze, M.D., PhD.Taking people
- Dana FarberBoston, United StatesContact: David Shulman, MDTaking people
- Ohio State UniversityColumbus, United StatesContact: Gabriel Tinoco, MDTaking people
- MD AndersonHouston, United StatesContact: Elise Nassif Haddad, MD, PhDTaking people
- University of MiamiMiami, United StatesContact: Gina D'Amato, MDTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Elizabeth J Davis, MDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Sujana Movva, MDTaking people
- Mayo ClinicRochester, United StatesContact: Brittany Siontis, MDTaking people
- Sarcoma Oncology Research CenterSanta Monica, United StatesContact: Allyssa LingadTaking people
About the trial
What the trial wants to find out
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.
The group in the trial
- Enrolled Subjects
Once enrolled subjects will provide Optional Archival Tissue, Optional Fresh tumor for a biopsy and blood collections at baseline, optional day 8 of cycle 1, day 1 of cycles 2-6 and at progression
Treatment: Plasma Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy
- Plain-language title
- Blood Markers in Patients With Metastatic Leiomyosarcoma Receiving ChemotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 June 2026